Arch Therapeutics Inc (ARTH) 0.5930 $ARTH
Arch Therapeutics Will Present at the 2016 Aegis Capital Growth Conference in Las Vegas, NV September 20-22, 2016
Marketwired - Thu Sep 15, 6:57AM CDT
FRAMINGHAM, MA--(Marketwired - Sep 15, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5™ devices for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, today announced it will be featured as a presenting company at the 2016 Aegis Capital Growth Conference. The presentation will take place at 1:00 PM PDT (4 PM EDT) on Wednesday, September 21st at The Encore at Wynn in Las Vegas, Nevada.
Arch Therapeutics Provides Corporate Update at the 18th Annual Rodman & Renshaw Global Investment Conference
Marketwired - Mon Sep 12, 6:08PM CDT
FRAMINGHAM, MA--(Marketwired - Sep 12, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company", developer of AC5™ devices for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, was featured as a presenting company today at the 18th Annual Rodman & Renshaw Global Investment Conference taking place at the Lotte New York Palace Hotel in New York City.
Arch Therapeutics Will Present 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016
Marketwired - Mon Aug 22, 10:03AM CDT
FRAMINGHAM, MA--(Marketwired - Aug 22, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company", developer of AC5™ devices for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, today announced that it will be featured as a presenting company at the 18th Annual Rodman & Renshaw Global Investment Conference taking place from September 11-13, 2016 at the Lotte New York Palace Hotel in New York, New York.
Arch Therapeutics' President and CEO, Terrence Norchi, MD, Featured on "Small Cap Spotlight" Podcast Broadcasted Globally on Publicwire
Marketwired - Fri Aug 19, 7:57AM CDT
Norchi Discusses Significance of Clinical Data, CE Mark Process and Additional Corporate Highlights
Arch Therapeutics Reports AC5 Topical Hemostatic Device Meets Primary and Secondary Endpoints in First Clinical Study
Marketwire Canada - Mon Aug 15, 5:57AM CDT
Clinical Safety and Performance of AC5 Successfully Demonstrated in Dermatology Procedure Performed on 46 Skin Lesion Patients With Bleeding Wounds
Arch Therapeutics Completes Patient Enrollment in Clinical Study of AC5
Marketwire Canada - Mon Jun 06, 6:57AM CDT
Data Expected During Summer 2016 After Completion of 30-Day Follow-Up and Subsequent Statistical Analysis
Arch Therapeutics Announces May 26, 2016 $3.4 Million Private Placement
Marketwired - Fri May 27, 8:00AM CDT
FRAMINGHAM, MA--(Marketwired - May 27, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company", developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that it has entered into subscription agreements with a group of accredited investors (the "Investors" to purchase approximately $3.4 million of the Company's securities in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder (the "Private Placement".
Arch Therapeutics Announces Issuance of Composition of Matter Patent Covering Self-Assembling Peptidomimetics
Marketwire Canada - Mon May 16, 6:57AM CDT
U.S. Patent Addresses Self-Assembling Peptidomimetics That Form Barrier Structures on Tissue and Inhibit or Prevent the Passage of Bodily Fluids and Contaminants
Arch Therapeutics Receives Notice of Allowance for Composition of Matter and Method of Use Patent Covering Solid Forms of Self-Assembling Peptides
Marketwire Canada - Tue May 10, 6:57AM CDT
U.S. Patent Addresses Controlling the Movement of Bodily Fluids With Meshes That Include Self-Assembling Peptides
Arch Therapeutics Receives Notice of Allowance for Patent Covering Systemic Applications for Self-Assembling Peptides
Marketwired - Tue May 03, 8:19PM CDT
U.S. Patent Addresses Use of the Self-Assembling Peptide Barrier Technology to Treat Disorders Involving Leaky Tight Junctions and Extracellular Matrix
Revenue up 354% in 3D Printing And Royalty Agreement with Fortune 500 Manufacturer - Other Stocks to Watch
ACCESSWIRE - Mon May 02, 7:30AM CDT
MIAMI, FL / ACCESSWIRE / May 2, 2016 / EmergingGrowth.com - Graphene 3D Lab, Inc. (OTCQB: GPHBF) just released its quarterly report for the period ending February 29, 2016 showing an increase in revenue of 354% over their November 30, 2016 quarter.
TERP: 13.30 (-0.15), GS: 166.94 (+0.73), UPL: 0.31 (unch), HPQ: 14.56 (unch)
Arch Therapeutics Will Present at the 2016 Aegis Capital Growth Conference in Las Vegas, NV September 20-22, 2016
Marketwired - Thu Sep 15, 6:57AM CDT
FRAMINGHAM, MA--(Marketwired - Sep 15, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5™ devices for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, today announced it will be featured as a presenting company at the 2016 Aegis Capital Growth Conference. The presentation will take place at 1:00 PM PDT (4 PM EDT) on Wednesday, September 21st at The Encore at Wynn in Las Vegas, Nevada. Arch Therapeutics Provides Corporate Update at the 18th Annual Rodman & Renshaw Global Investment Conference
Marketwired - Mon Sep 12, 6:08PM CDT
FRAMINGHAM, MA--(Marketwired - Sep 12, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of AC5™ devices for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, was featured as a presenting company today at the 18th Annual Rodman & Renshaw Global Investment Conference taking place at the Lotte New York Palace Hotel in New York City. Arch Therapeutics Will Present 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016
Marketwired - Mon Aug 22, 10:03AM CDT
FRAMINGHAM, MA--(Marketwired - Aug 22, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of AC5™ devices for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, today announced that it will be featured as a presenting company at the 18th Annual Rodman & Renshaw Global Investment Conference taking place from September 11-13, 2016 at the Lotte New York Palace Hotel in New York, New York. Arch Therapeutics' President and CEO, Terrence Norchi, MD, Featured on "Small Cap Spotlight" Podcast Broadcasted Globally on Publicwire
Marketwired - Fri Aug 19, 7:57AM CDT
Norchi Discusses Significance of Clinical Data, CE Mark Process and Additional Corporate Highlights
Arch Therapeutics Reports AC5 Topical Hemostatic Device Meets Primary and Secondary Endpoints in First Clinical Study
Marketwire Canada - Mon Aug 15, 5:57AM CDT
Clinical Safety and Performance of AC5 Successfully Demonstrated in Dermatology Procedure Performed on 46 Skin Lesion Patients With Bleeding Wounds
Arch Therapeutics Completes Patient Enrollment in Clinical Study of AC5
Marketwire Canada - Mon Jun 06, 6:57AM CDT
Data Expected During Summer 2016 After Completion of 30-Day Follow-Up and Subsequent Statistical Analysis
Arch Therapeutics Announces May 26, 2016 $3.4 Million Private Placement
Marketwired - Fri May 27, 8:00AM CDT
FRAMINGHAM, MA--(Marketwired - May 27, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that it has entered into subscription agreements with a group of accredited investors (the "Investors" to purchase approximately $3.4 million of the Company's securities in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder (the "Private Placement". Arch Therapeutics Announces Issuance of Composition of Matter Patent Covering Self-Assembling Peptidomimetics
Marketwire Canada - Mon May 16, 6:57AM CDT
U.S. Patent Addresses Self-Assembling Peptidomimetics That Form Barrier Structures on Tissue and Inhibit or Prevent the Passage of Bodily Fluids and Contaminants
Arch Therapeutics Receives Notice of Allowance for Composition of Matter and Method of Use Patent Covering Solid Forms of Self-Assembling Peptides
Marketwire Canada - Tue May 10, 6:57AM CDT
U.S. Patent Addresses Controlling the Movement of Bodily Fluids With Meshes That Include Self-Assembling Peptides
Arch Therapeutics Receives Notice of Allowance for Patent Covering Systemic Applications for Self-Assembling Peptides
Marketwired - Tue May 03, 8:19PM CDT
U.S. Patent Addresses Use of the Self-Assembling Peptide Barrier Technology to Treat Disorders Involving Leaky Tight Junctions and Extracellular Matrix
Revenue up 354% in 3D Printing And Royalty Agreement with Fortune 500 Manufacturer - Other Stocks to Watch
ACCESSWIRE - Mon May 02, 7:30AM CDT
MIAMI, FL / ACCESSWIRE / May 2, 2016 / EmergingGrowth.com - Graphene 3D Lab, Inc. (OTCQB: GPHBF) just released its quarterly report for the period ending February 29, 2016 showing an increase in revenue of 354% over their November 30, 2016 quarter.
TERP: 13.30 (-0.15), GS: 166.94 (+0.73), UPL: 0.31 (unch), HPQ: 14.56 (unch)
